© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Contralateral Breast Cancer and Thromboembolic Events in African American Women Treated With Tamoxifen
Affiliations of authors: Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (WMS); National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, University of Pittsburgh, Pittsburgh, PA (JW, JB, WC); Aultman Hospital Cancer Center, Canton, OH (EM); National Surgical Adjuvant Breast and Bowel Project Operations Center, Pittsburgh, PA (LG); Fox Chase Cancer Center, Philadelphia, PA (JJ); National Surgical Adjuvant Breast and Bowel Project Operations Center and Allegheny General Hospital, Pittsburgh, PA (DLW).
Correspondence to: Worta McCaskill-Stevens, MD, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd., EPN 2014, Bethesda, MD 20892 (e-mail: wm57h{at}nih.gov)
Background: Information about breast cancer treatment and prevention in African American women is scant, and recommendations for therapy from clinical trials for breast cancer are based primarily on data obtained from white women. Methods: We compared the effects of tamoxifen on risk of contralateral breast cancer and thromboembolic events in African American women and white women with a history of primary breast cancer. Data from 13 National Surgical Adjuvant Breast and Bowel Project clinical trials were pooled for analyses of time to contralateral breast cancer as a first event (eight trials and 10 619 patients) and of time to any thromboembolic phenomenon as a first event (all 13 trials and 20 878 patients). Risk factors for contralateral breast cancer and thromboembolic events among all women were determined using univariate proportional hazards models. (For each racial group, the rate of events associated with tamoxifen use was calculated as the ratio of the incidence rate with tamoxifen to that without tamoxifen.) Proportional hazards regression models were used to calculate 95% confidence intervals (CIs) and risk ratios. All statistical tests were two-sided. Results: Risk factors for contralateral breast cancer were body mass index (BMI) and lymph node positivity; those for thromboembolic events were BMI and age. In women of both ethnicities with estrogen receptor–positive breast cancer, those who took tamoxifen experienced a similar reduction in contralateral breast cancer (risk ratio for African American women = 0.74, 95% CI = 0.46 to 1.17, n = 690; risk ratio for white women = 0.76, 95% CI = 0.59 to 0.98, n = 9929; P = .92). Tamoxifen was also associated with an increase in thromboembolic events. The relative risk for thromboembolic events was higher in both African American and white women treated with tamoxifen and chemotherapy than in those who were treated with tamoxifen alone (risk ratio for African American women = 10.70, 95% CI = 5.94 to 19.28 versus 2.16, 95% CI = 1.26 to 3.71; n = 1842; risk ratio for white women = 15.49, 95% CI = 9.53 to 25.17 versus 3.13, 95% CI = 2.04 to 4.79, n = 19 036), and this effect was similar between the races (P = .10). Conclusions: African American and white women appear to have the same risks of contralateral breast cancer and thromboembolic events in response to tamoxifen treatment.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: Tamoxifen's Risks Similar in African American and White Women
- Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1727.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  B Moy, D Tu, J. Pater, J. Ingle, L. Shepherd, T. Whelan, and P. Goss Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer Ann. Onc., November 1, 2006; 17(11): 1637 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher Thromboembolism in cancer patients: pathogenesis and treatment. Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A. Newman, K. A. Griffith, I. Jatoi, M. S. Simon, J. P. Crowe, and G. A. Colditz Meta-Analysis of Survival in African American and White American Patients With Breast Cancer: Ethnicity Compared With Socioeconomic Status J. Clin. Oncol., March 20, 2006; 24(9): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Taylor, J. T. Wright Jr, R. S. Cooper, B. M. Psaty, A. L. Taylor, J. T. Wright Jr, R. S. Cooper, and B. M. Psaty Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Circulation, December 6, 2005; 112(23): 3654 - 3666. [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Dunn Hormonal Interventions: From Adjuvant Therapy to Breast Cancer Prevention Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 185 - 188. [Full Text] [PDF]
|
|